Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 11/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234710 | 0.98 | NAAA (0.44) | NAAAKMT2AEPHX1ASAH1ACP1 | |
| SCHEMBL5237250 | 0.94 | KMT2A (0.43) | NAAAKMT2AEPHX1ACP1CPN1 | |
| SCHEMBL29068162 | 0.88 | KMT2A (0.46) | NAAAKMT2AEPHX1ACP1LMNA | |
| SCHEMBL9732440 | 0.88 | KMT2A (0.46) | NAAAKMT2AEPHX1ACP1LMNA | |
| SCHEMBL5237332 | 0.85 | CHRNB2 (0.41) | NAAAKMT2AEPHX1ACP1LMNA | |
| SCHEMBL28759836 | 0.83 | EPHX1 (0.43) | NAAAKMT2AEPHX1ASAH1 | |
| SCHEMBL5232032 | 0.82 | CHRNB2 (0.41) | NAAAKMT2AEPHX1ACP1LMNA | |
| SCHEMBL8893237 | 0.81 | EPHX1 (0.59) | NAAAEPHX1ASAH1LMNAAPOBEC3A | |
| SCHEMBL14403742 | 0.80 | HRH3 (0.42) | NAAAKMT2AACP1CPN1CPB2 | |
| SCHEMBL10263186 | 0.79 | EPHX1 (0.61) | NAAAEPHX1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246030-A1 | NOVEL ADENINE DERIVATIVES | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320905-B1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-104530048-B | Adenine derivatives | 葛兰素史密丝克莱恩有限责任公司 | 2016-09-14 | — | — | CN | disclosed |
| CN-104530048-A | Novel adenine derivatives | GLAXOSMITHKLINE LLC | 2015-04-22 | — | — | CN | disclosed |
| CN-102176911-B | Novel adenine derivatives | GLAXOSMITHKLINE LLC | 2014-12-10 | — | — | CN | disclosed |
| US-8802684-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563717-B2 | Adenine derivatives | GLAXOSMITHKLINE LLC (US) | 2013-10-22 | — | — | US | disclosed |
| CN-102176911-A | Novel adenine derivatives | GLAXOSMITHKLINE LLC | 2011-09-07 | — | — | CN | disclosed |
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2320905-A1 | NOVEL ADENINE DERIVATIVES | Smithkline Beecham Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010018134-A1 | NOVEL ADENINE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144136-A1 | NOVEL ADENINE DERIVATIVES | STING1, IFNG, IFNAR1 | NAAA 567/4885KMT2A 3754/4885EPHX1 523/4885 |
| US-20140024664-A1 | NOVEL ADENINE DERIVATIVES | IFNAR1, STING1, IFNG | NAAA 510/4885KMT2A 3247/4885EPHX1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.